Keyword Search Results for "bleeding"

Owen, J., Friedman, K. D., Grossman, B. A., Wilkins, C., Berke, A. D., Powers, E. R. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator Journal of clinical investigation. 1987;79(6):1642-7. Abstract

Rao, A. K., Pratt, C., Berke, A., Jaffe, A., Ockene, I., Schreiber, T. L., Bell, W. R., Knatterud, G., Robertson, T. L., Terrin, M. L. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase Journal of the American College of Cardiology. 1988;11(1):11-Jan. Abstract

Simoons, M. L., Maggioni, A. P., Knatterud, G., Leimberger, J. D., de Jaegere, P., van Domburg, R., Boersma, E., Franzosi, M. G., Califf, R., Schroder, R., et al., Individual risk assessment for intracranial haemorrhage during thrombolytic therapy Lancet. 1993;342(8886-8887):1523-8. Abstract

Antman, E. M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial Circulation. 1994;90:1624-30. Abstract

Flaker, G. C., Bartolozzi, J., Davis, V., McCabe, C., Cannon, C. P. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction Archives of internal medicine. 1994;154(13):1492-6. Abstract

The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol. 1997;29:1474-82. Abstract

Giugliano, R. P., McCabe, C. H., Antman, E. M., Cannon, C. P., Van de Werf, F., Wilcox, R. G., Braunwald, E. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage Am Heart J. 2001;141(5):742-50. Abstract

Morrow, D. A., Murphy, S. A., McCabe, C. H., Mackman, N., Wong, H. C., Antman, E. M. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial Eur Heart J. 2005;26(7):682-8.

Atar, S., Cannon, C. P., Murphy, S. A., Rosanio, S., Uretsky, B. F., Birnbaum, Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial Am Heart J. 2006;151(5):976 e1-6. Abstract

Kirtane, A. J., Piazza, G., Murphy, S. A., Budiu, D., Morrow, D. A., Cohen, D. J., Peterson, E., Lakkis, N., Herrmann, H. C., Palabrica, T. M., Gibson, C. M. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial J Am Coll Cardiol. 2006;47(12):2374-9.

Cannon, C. P., Husted, S., Harrington, R. A., Scirica, B. M., Emanuelsson, H., Peters, G., Storey, R. F. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial J Am Coll Cardiol. 2007;50(19):1844-51. Abstract

Husted, S., Harrington, R. A., Cannon, C. P., Storey, R. F., Mitchell, P., Emanuelsson, H. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial Int J Clin Pract. 2009;63(4):667-70. Abstract

Giugliano, R. P., Giraldez, R. R., Morrow, D. A., Antman, E. M., Gibson, C. M., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Braunwald, E. Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial Eur Heart J. 2010;31(17):2103-10. Abstract

Kadakia, M. B., Desai, N. R., Alexander, K. P., Chen, A. Y., Foody, J. M., Cannon, C. P., Wiviott, S. D., Scirica, B. M., National Cardiovascular Data, Registry Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines) JACC Cardiovasc Interv. 2010;3(11):1166-77. Abstract

Lopes, R. D., Peterson, E. D., Chen, A. Y., Roe, M. T., Wang, T. Y., Ohman, E. M., Magid, D. J., Ho, P. M., Wiviott, S. D., Scirica, B. M., Alexander, K. P. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry JACC Cardiovasc Interv. 2010;3(6):669-77. Abstract

Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., Serebruany, V., Valgimigli, M., Vranckx, P., Taggart, D., Sabik, J. F., Cutlip, D. E., Krucoff, M. W., Ohman, E. M., Steg, P. G., White, H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation. 2011;123(23):2736-47.

Gibson, C. Michael, Levitan, Bennett, Murphy, Sabina A, Yuan, Zhong, Chakrabarti, Anjan, Lee, Michael, Mega, Jessica, Braunwald, Eugene Abstract 13152: A Net Clinical Outcome Analysis Comparing Fatal or Irreversible Ischemic and Bleeding Events in ATLAS ACS 2 - TIMI 51 Circulation. 2012;126(21 Supplement):A13152.

Pride, Yuri, Mohanavelu, Satishkumar, Mega, Jessica, Braunwald, Eugene, Gibson, C. Michael Abstract 9944: Temporal Relationship Between Major Hemorrhagic Events and Mortality among Patients with Recent Acute Coronary Syndrome: Insights from ATLAS ACS 2-TIMI 51 Circulation. 2012;126(21 Supplement):A9944.

Subherwal, S., Peterson, E. D., Chen, A. Y., Roe, M. T., Washam, J. B., Gage, B. F., Bach, R. G., Bhatt, D. L., Wiviott, S. D., Lopes, R. D., Alexander, K. P., Wang, T. Y. Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry Circulation. 2012;125(11):1414-23. Abstract

Desai, N. R., Peterson, E. D., Chen, A. Y., Wiviott, S. D., Sabatine, M. S., Alexander, K. P., Roe, M. T., Shah, B. R. Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - A report from the National Cardiovascular Data Registry Am Heart J. 2013;166(6):1043-1049 e1. Abstract

Ducrocq, G., Amarenco, P., Labreuche, J., Alberts, M. J., Mas, J. L., Ohman, E. M., Goto, S., Lavallee, P., Bhatt, D. L., Steg, P. G. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease Circulation. 2013;127(6):730-8. Abstract

Mega, J. L., Braunwald, E., Murphy, S. A., Plotnikov, A., Burton, P., Kiss, R. G., Parkhomenko, A., Tendera, M., Widimsky, P., Gibson, C. M. Rivaroxaban in Patients Stabilized after a ST-Elevation Myocardial Infarction: Results from the ATLAS ACS 2-TIMI 51 Trial J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Murphy, S., Bohula May, Erin A., Bonaca, M. P., Scirica, B., Braunwald, E. B., Morrow, D., Brigham and Women's Hospital Procedural Bleeding with Vorapaxar versus Placebo in TRA 2P - TIMI 50 Trial Journal of the American College of Cardiology. 2013;61(10):A30.

Reed, G. W., Cannon, C. P. Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting Clin Cardiol. 2013;NA(NA):NA. Abstract

Xian, Y., Chen, A. Y., Thomas, L., Roe, M. T., Subherwal, S., Cannon, C. P., Pollack, C. V., Jr., Fonarow, G. C., Kosiborod, M., Peterson, E. D., Alexander, K. P. Sources of Hospital-Level Variation in Major Bleeding Among Patients With Non-ST-Segment Elevation Myocardial Infarction: A Report From the National Cardiovascular Data Registry (NCDR) Circ Cardiovasc Qual Outcomes. 2014;7(2):236-43. Abstract